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differed: 17.5 mg/m2/day (ch14.18-UTC) and 25 mg/m2/
day (ch14.18-NCI). Patients received one product dur-
ing therapy cycles 1 and 2, the other during cycles 3–5. 
Ch14.18 pharmacokinetic profile characterization used 
population modeling (NONMEM® version 7.2). A two-
compartment model with first-order distribution and 
elimination processes described pharmacokinetic data. 
Estimated product parameters were normalized to UTC 
nominal dose. For pharmacokinetic comparability, the final 
model was used to estimate exposure ratios (UTC/NCI) and 
associated 90 % confidence intervals (CIs) for area under 
the curve from time zero to infinity (AUCinf) and maximum 
concentration (Cmax). All comparisons were based on a 
standardized single-dose regimen (17.5 mg/m2 over 10 h).
Results Final-model pharmacokinetic parameters were 
similar to previously published ch14.18-NCI parameters 
and comparable for UTC and NCI products. Products’ sys-
temic exposures were comparable, with 90 % CIs around 
Abstract 
Purpose Dinutuximab (Unituxin™; ch14.18), a monoclo-
nal antibody against disialoganglioside, improved survival 
as part of post-consolidation therapy for high-risk neuro-
blastoma. United Therapeutics Corporation (UTC) assumed 
ch14.18 production from the National Cancer Institute 
(NCI); this study evaluates pharmacokinetic comparability, 
safety, and tolerability of UTC and NCI products.
Methods In this randomized, two-sequence crossover 
study, 28 patients aged ≤8 years with high-risk neuroblas-
toma received equivalent ch14.18-UTC or ch14.18-NCI 
doses. Despite comparable protein content, nominal doses 
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ratios for AUCinf (0.96; 90 % CI 0.88–1.04) and Cmax (1.04; 
90 % CI 0.98–1.11) within standard bioequivalence bounds 
(90 % CI 0.80–1.25). Products’ adverse events were similar 
and consistent with those previously reported.
Conclusions Equivalent actual ch14.18-UTC and 
ch14.18-NCI doses produced comparable exposures, with 
no notable safety or tolerability differences.
Keywords ch14.18 · Dinutuximab · Pharmacokinetics · 
Safety · Tolerability · Unituxin
Introduction
Neuroblastoma, which is a tumor of the autonomic nervous 
system, accounts for approximately 7 % of cancers in chil-
dren <15 years of age [1]; ~90 % of patients are <5 years of 
age at diagnosis [1]. The disease is heterogeneous, complex, 
and frequently aggressive [2]. At diagnosis, approximately 
40 % of patients have high-risk disease [3], based on fac-
tors such as age, disease stage, and biologic markers (e.g., 
unfavorable histopathology, tumor amplification of MYCN 
oncogene) [4]. High-risk neuroblastoma is treated with 
dose-intensive chemotherapy and surgery, followed by mye-
loablative chemotherapy with autologous stem cell trans-
plantation (ASCT), local radiation therapy, and maintenance 
with isotretinoin [5, 6]. Despite this intensive treatment, 
many patients relapse or have treatment-refractory disease, 
and 5-year event-free survival rates are ≤50 % [4, 7].
Disialoganglioside (GD2) is a surface glycolipid antigen 
that is strongly expressed on neuroblastoma tumor cells, 
with limited expression in normal human tissues [8]. GD2 
is an important molecular target for immunotherapeutic 
approaches to treating neuroblastoma, and anti-GD2 mono-
clonal antibodies are efficacious in patients with high-risk 
neuroblastoma.
Dinutuximab (Unituxin™), formerly called ch14.18, is 
a murine–human chimeric anti-GD2 monoclonal antibody 
[9]. Initial trials demonstrated that ch14.18 at a dose of 
25 mg/m2 infused over 10 h daily for 4 consecutive days 
could be incorporated into treatment regimens containing 
isotretinoin and the immunomodulators sargramostim and 
aldesleukin [10–12]. Subsequently, the Children’s Oncol-
ogy Group (COG) conducted a randomized phase 3 clinical 
trial (ANBL0032) comparing ch14.18 administered with 
isotretinoin, sargramostim, and aldesleukin versus isotreti-
noin alone in patients with high-risk neuroblastoma who 
had responded to induction therapy, surgery, ASCT, and 
radiotherapy [12]. The trial demonstrated improved event-
free survival (p = 0.01) and overall survival (p = 0.02) 
at 2 years on the immunotherapy arm [12]. Based on the 
results of this trial, dinutuximab received US Food and 
Drug Administration (FDA), and European Medicines 
Agency (EMA) approval for the treatment of high-risk 
neuroblastoma.
As part of a collaborative research agreement and devel-
opment agreement (CRADA) with the National Cancer 
Institute (NCI), United Therapeutics Corporation (UTC) 
has licensed ch14.18 and assumed production. The nomi-
nal (i.e., labeled) dose of the UTC product (17.5 mg/m2) 
differs from the dose of the prior NCI product (25 mg/m2) 
because of a difference in the extinction coefficient used to 
determine the protein concentration during the manufac-
turing process. Despite the change in nominal dosing, the 
amount of antibody delivered per dose is equivalent for the 
two products. Corrections for this difference in the prod-
ucts’ nominal dose must be made when comparing dose-
dependent pharmacokinetic parameters, such as clearance 
and volumes of distribution.
The primary objective of this study was to compare the 
pharmacokinetics of ch14.18 manufactured by these two 
independent facilities (i.e., NCI and UTC). The secondary 




Study DIV-NB-201 was a phase 2 randomized, open-label, 
two-sequence crossover trial evaluating ch14.18 in patients 
with high-risk neuroblastoma scheduled to receive immu-
notherapy. The clinical trial was conducted in accord-
ance with the ethical principles of the Declaration of Hel-
sinki and the International Conference on Harmonization 
E6 Good Clinical Practice Guideline. The protocol was 
approved by the Institutional Review Board at each par-
ticipating site, and the parents or guardians provided writ-
ten informed consent with patient assent, as appropriate. 
Patients were randomized 1:1 to receive either ch14.18-
UTC or ch14.18-NCI during cycles 1 and 2, followed by 
ch14.18 from the other product during cycles 3–5. Eligible 
patients were randomized between 56 and 105 days after 
ASCT. Randomization must have occurred after the com-
pletion of tumor assessments post-ASCT and radiotherapy, 
if applicable.
Patients and treatment
Eligible patients were ≤8 years of age, had a diagnosis 
of high-risk neuroblastoma, and had completed stand-
ard induction therapy, surgery, myeloablative therapy and 
ASCT, and local radiotherapy to the primary tumor if indi-
cated. Patients must have achieved a partial response or 
better per International Neuroblastoma Response Criteria 
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(INRC) [13] at the primary site, soft tissue metastases, 
bone metastases, and bone marrow response at the pre-
ASCT evaluation. Prior to enrollment, a determination of 
residual disease was performed, and patients could not 
have progressive disease per INRC except for protocol-
specified bone marrow response to account for sampling 
errors. Patients were also required to have a Lansky perfor-
mance status of ≥50 %; a total absolute phagocyte count 
≥1000/μL; adequate renal, hepatic, cardiac, pulmonary, 
and central nervous system function; and a life expectancy 
of ≥2 months. Patients were excluded if they had received 
prior anti-GD2 antibody therapy or had prior vaccine ther-
apy for the treatment of neuroblastoma. Patients were also 
excluded if they had received or planned to receive antican-
cer therapies, cytokines, or growth factors not included in 
the prescribed protocol therapy during the study or immu-
nosuppressive drugs other than for acute allergic reactions 
and anaphylaxis during the study.
The study material manufactured by NCI used a theoret-
ical extinction coefficient of 1.00 to calculate the concen-
tration of antibody, whereas UTC material used an actual 
extinction coefficient of 1.41 to determine the antibody 
concentration. Thus, each 25 mg/m2 dose of ch14.18-NCI 
contains the same amount of ch14.18 as a 17.5-mg/m2 dose 
of ch14.18-UTC, making the respective dosing equiva-
lent despite differences in the nominal doses. The dosing 
schema in this study is summarized in Table 1. During the 
first five cycles, patients received ch14.18-UTC or ch14.18-
NCI intravenously (IV) over 10–20 h daily for four consec-
utive days repeated every 28 days, with one product admin-
istered during cycles 1 and 2 and the other product during 
cycles 3, 4, and 5. All patients received sargramostim IV 
or subcutaneously (SC) (250 mcg/m2/day for 14 days) on 
cycles 1, 3, and 5 prior to, during, and following ch14.18, 
and aldesleukin IV (3 MIU/m2/day for 4 days as a continu-
ous infusion for the first week, followed by 4.5 MIU/m2/
day for 4 days as a continuous infusion concurrently with 
ch14.18 for the second week) during cycles 2 and 4. In 
addition, all patients received six cycles of isotretinoin over 
14 days (80 mg/m2/day orally twice daily for >12 kg and 
2.67 mg/kg orally twice daily for ≤12 kg) after completion 
of ch14.18 therapy.
In addition to study treatment, supportive care meas-
ures, including the use of narcotics and other concomitant 
medications, were required for the treatment of anticipated 
toxicities.
Assessments
Pharmacokinetic blood samples for the determination of 
ch14.18 plasma concentrations were obtained at 22 time 
points over the course of the treatment (Table 1). Samples 
were drawn prior to the first dose of sargramostim on cycle 
1 and the first ch14.18 infusion on cycle 3; after the end 
of each daily ch14.18 infusion; and 10–14 h, 3–5 days, 
and 8–11 days after the fourth ch14.18 infusion on cycles 
1 and 3. Sampling during cycles 2 and 4 occurred prior to 
aldesleukin, prior to the first ch14.18 dose, and at the end 
of the fourth daily ch14.18 infusion on cycle 4 only. A final 
sample was obtained at study end, within 2 weeks of the 
final isotretinoin dose on cycle 6. Blood samples for the 
analysis of human anti-chimeric antibody (HACA) were 
obtained prior to ch14.18 dosing in each cycle. Plasma 
from each sample was isolated by centrifugation, frozen, 
and shipped to Burleson Research Technologies, Mor-
risville, NC, for storage. Samples were shipped to Bio-
Agilytix, Durham, NC, where ch14.18 and HACA plasma 
concentrations were measured using validated assays: a 
sandwich immunoassay employing an electrochemilumi-
nescence platform to measure ch14.18, and a Meso Scale 
Discovery electrochemiluminescent assay (Meso Scale 
Diagnostics, Rockville, MD) with a lower limit of quantifi-
cation of a titer of 10 to measure HACA.
Because of the study complexity and data limitations, a 
model-based approach, rather than a traditional noncom-
partmental bioequivalence analysis, was used to assess 
the pharmacokinetic comparability of ch14.18-UTC and 
ch14.18-NCI. Detailed pharmacokinetic data from nine 
patients with high-risk neuroblastoma enrolled in a previ-
ous pharmacokinetic study of ch14.18-NCI at the Chil-
dren’s Hospital of Philadelphia by Desai [14] were used 
to develop a structural population pharmacokinetic model. 
The final model was a two-compartment model with first-
order distribution and elimination processes. To account 
for the effects of body size on pharmacokinetic parameters, 
actual body weight was included as a predetermined allo-
metric covariate on all clearance and volume of distribu-
tion parameters. Estimated pharmacokinetic parameters 
included clearance from the central compartment (CL), 
distributional clearance (Q), volume of the central com-
partment (V1), volume of the peripheral compartment 
(V2), steady-state volume of distribution (Vss), first-order 
elimination rate constant (Kel), and first-order distribution 
rate constants (central-to-peripheral [Kcp]; peripheral-to-
central [Kpc]). The final structural model for the data from 
the prior Desai study was then used to estimate pharma-
cokinetic parameters for ch14.18-UTC and ch14.18-NCI 
in the formal comparability study (DIV-NB-201). This 
staged analysis approach was taken to avoid the potential 
for inflated alpha error associated with iterative model 
development using the formal comparability data from 
DIV-NB-201.
Because calculations of some pharmacokinetic param-
eters are dependent on the nominal dose of drug, differ-
ences in the nominal doses of ch14.18-UTC and ch14.18-
NCI will affect pharmacokinetic parameter estimates. In 
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the Desai study [14], pharmacokinetic parameter estimates 
were based on nominal dosing units of ch14.18-NCI. 
Therefore, when comparing dose-dependent pharmacoki-
netic parameters generated using UTC and NCI nominal 
doses, appropriate corrections were made.
To formally assess the pharmacokinetic bioequivalence 
of the UTC and NCI products, maximum concentration 
(Cmax) and area under the curve from time zero to infin-
ity (AUCinf) were calculated using the population phar-
macokinetic parameter estimates of CL and V from DIV-
NB-201 and appropriate closed-form equations for Cmax 
and AUCinf. Variability in exposure estimates was captured 
by sampling the posterior distribution of pharmacokinetic 
parameter estimates using the NONMEM® Markov Chain 
Monte Carlo methodology. To allow for valid comparisons, 
all calculations were based on a standardized single dose of 
17.5 mg/m2 infused over 10 h, using nominal UTC doses. 
Pharmacokinetic bioequivalence was assessed by calcula-
tion of ratios (UTC/NCI) for AUCinf and Cmax with 90 % 
confidence interval (CI) of the ratios. AUCinf was the pri-
mary comparability end point. Bioequivalence was estab-
lished if the 90 % CIs for the exposure ratios were com-
pletely contained within accepted bioequivalence bounds 
(0.80–1.25).
Safety assessments included adverse event reporting, 
physical examinations, clinical laboratory assessments, and 
treatment-related changes in electrocardiograms (ECGs). 
Safety analyses were performed on all patients receiving at 
least one study drug dose. No inferential statistical analyses 
of safety data were planned.
Results
Twenty-eight patients were enrolled, and 14 patients were 
randomized to each treatment sequence. Patient charac-
teristics are summarized in Table 2 with no differences in 
demographics by sequence. A summary of concomitant 
medications used by patients during cycles 1–5 is presented 
in Supplemental Table 1. Patients’ completion or discon-
tinuation of study therapy is summarized in Table 3. One 
patient was excluded from the pharmacokinetic analysis 
because of a neutralizing antibody response that interfered 
with measurement of ch14.18 concentration. All 28 patients 
received at least one dose of ch14.18 and were included in 
the safety analysis. Seven patients discontinued the study 
prior to completion of the planned six cycles; reasons 
were disease progression (n = 2), adverse events (n = 2), 
or withdrawal of consent (n = 1). Two patients received 
cycles 1–5 in the USA and returned to their home coun-
try to complete cycle 6. Ch14.18 was administered over a 
median duration of 11 h (range 10–20 h). 
Immunogenicity
Six of 27 patients had detectable HACA during the study. 
Only one patient (17 %) had a pharmacokinetic-neutral-
izing response (detected in cycle 3) and was therefore 
excluded from the pharmacokinetic analysis.
Pharmacokinetics
Representative concentration time profiles for ch14.18-
UTC and ch14.18-NCI from a single patient are presented 
in Fig. 1a (semilog), b (linear). A comparison of the phar-
macokinetic profiles indicates similar exposures for both 
products. Population mean concentration time profiles 
are shown in Supplemental Figure 1. Summary statistics 
of post hoc pharmacokinetic parameters are presented in 
Table 4 for each product, separately and combined. Dose-
dependent pharmacokinetic parameters were normalized to 
the nominal ch14.18-UTC dose. Clearance, volumes of dis-
tribution, and rate constants were equivalent for the NCI- 
and UTC-manufactured products. 
Following standardized single-dose regimens, popula-
tion pharmacokinetic estimates for AUCinf were 431 µg·h/
mL for ch14.18-UTC and 413 µg·h/mL for ch14.18-NCI 
(ratio = 1.04; 90 % CI 0.98–1.11). Population pharmacoki-
netic estimates for Cmax were 6.57 µg/mL and 6.88 µg/mL, 
respectively (ratio = 0.96; 90 % CI 0.88–1.04). The 90 % 
CIs for exposure ratios of AUCinf and Cmax were contained 
within the standard bioequivalence bounds (0.80–1.25), 
consistent with comparable exposure between products.
Safety
All 28 randomized patients were included in the safety 
analyses and had at least one treatment-related adverse 
event (TRAE) overall and at least one TRAE attributed to 
ch14.18. Overall, a total of 1945 TRAEs were reported, 
with most being grades 1–3. The most commonly reported 
TRAEs included pyrexia (100 %), hypoalbuminemia 
(96 %), hypokalemia (96 %), hyponatremia (82 %), cough 
(75 %), increased alanine aminotransferase (ALT) (68 %), 
anemia (68 %), hypocalcemia (68 %), pain (68 %), pruri-
tus (68 %), increased aspartate aminotransferase (AST) 
(64 %), hypertriglyceridemia (64 %), and abdominal pain 
(61 %). Although differences between products were seen 
for individual adverse events, evaluation over the entire 
study showed no notable differences in TRAE incidence 
by manufacturer, either overall or attributable to ch14.18. 
Pain-related TRAEs were generally similar between treat-
ment sequences; the most commonly reported pain-related 
events in the ch14.18-UTC and ch14.18-NCI groups were 
pain (59 and 44 %), abdominal pain (48 and 41 %), and 
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pain in extremity (33 and 41 %), respectively. Pain-related 
TRAEs were most commonly reported during cycles 
1, 2, and 4 (93, 74, and 71 %, respectively). Allergic-
type adverse events were also generally similar between 
ch14.18-UTC and ch14.18-NCI groups, with the most 
commonly reported events (i.e., ≥15 % of patients) includ-
ing urticaria (30 vs. 26 %), peripheral edema (15 vs. 11 %), 
pruritus (63 vs. 52 %), and rash (26 vs. 26 %), respectively, 
and occurred most frequently in cycles 1, 2, and 4.
Table 5 summarizes grade 3 or higher TRAEs consid-
ered by the investigator to be attributable to ch14.18 in 
≥10 % of patients. The most common grade ≥3 events 
were pyrexia, anemia, hypokalemia, and hyponatremia, 
with no discernible differences between study drugs. Other 
safety assessments, including clinical laboratories, physi-
cal examinations, and ECGs, were generally consistent 
between UTC- and NCI-manufactured ch14.18.
Discussion
The NCI-manufactured ch14.18 was used in the pivotal 
randomized phase 3 trial that demonstrated the efficacy 
of ch14.18 combined with sargramostim, aldesleukin, and 
isotretinoin administered as continuation therapy for high-
risk neuroblastoma [12]. This randomized crossover study 
comparing equivalent doses of ch14.18-UTC (17.5 mg/m2) 
and ch14.18-NCI (25 mg/m2) was conducted to confirm 
equivalence of the pharmacokinetic and safety profiles of 
the two products.
Pharmacokinetic parameters were estimated by fitting 
a two-compartment pharmacokinetic model to individual 
concentration–time data. The products were formally com-
pared using the results of a model-based bioequivalence 
analysis, which showed equivalent systemic exposures as 
measured by the AUCinf for ch14.18-UTC and ch14.18-
NCI, and 90 % CIs about the geometric least-squares mean 
ratios for AUCinf and Cmax within standard bioequivalence 
bounds (90 % CI 0.80–1.25). Clearance, volume of distri-
bution, and rate constants were also equivalent between the 
UTC and NCI products.
For this analysis, dose-dependent pharmacokinetic 
parameters were derived using the ch14.18-UTC nominal 
dose of 17.5 mg/m2. Historical parameters, such as CL and 
volumes of distribution, for the ch14.18-NCI material were 
derived using a 25-mg/m2 dose and require a correction 
factor of 0.7 for comparison with ch14.18-UTC material.
Data from an independent study (CHP1002) were used 
to develop a pharmacokinetic model for ch14.18. This 
model was then used to estimate pharmacokinetic param-
eters for the comparability study (DIV-NB-201). This 
approach was taken to avoid the potential for inflated 
alpha error associated with iterative model development 
based on the formal comparability data (DIV-NB-201). A 
model-based approach (rather than a traditional noncom-
partmental bioequivalence analysis) was chosen to assess 
Table 1  Dosing schema and pharmacokinetic assessment schedule
a Day 0, up to 3 days prior to initial dose of sargramostim. b End of infusion, within 15 min of completion (days 3 and 59), preinfusion (day 59). 
c End of infusion, within 15 min of completion (days 4–6, 60–62). d 10–14 h post-completion of ch14.18 infusion (days 7 and 63). e Single sam-
ple between days 9–11, 14–17, 65–67, and 70–73. f Single sample, prior to aldesleukin (days 24 and 80). g Preinfusion of the first ch14.18 dose 
(days 31 and 87). h Immediately following the fourth daily ch14.18 infusion (day 90). i End of study within 2 weeks of the final isotretinoin dose 
(cycle 6, day 163)
Cycles 1, 3, and 5 (24 days in duration)
Cycle day 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15–24
Sargramostim X X X X X X X X X X X X X X
ch14.18 X X X X
Isotretinoin X X X X X
Pharmacokinetic assessments 
(cycles 1 and 3 only)
Xa Xb,c Xc Xc Xc Xd Xd Xd Xd Xe Xe
Cycles 2, 4, and 6 (32 days in duration)
Cycle day
(cycles 2 and 4)
0 1 2 3 4 5 6 7 8 9 10 11 12–14 15–28 29–32
Aldesleukin X X X X X X X X




(cycles 2, 4, and 6)
Xf Xg Xh Xi
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the pharmacokinetic comparability of ch14.18-UTC and 
ch14.18-NCI because of data limitations and the com-
plexity of DIV-NB-201. The pharmacokinetic parameters 
derived from the population model for the CHP1002 study 
were comparable to those previously published by Desai 
et al. [14]. The Desai analysis was also based on a two-
compartment structural model; however, the methodology 
used for parameter estimation differed from the current 
Table 2  Patient demographic 
and baseline characteristics
ASCT autologous stem cell transplantation, NCI National Cancer Institute, UTC United Therapeutics Cor-
poration
a Patients were required to undergo ASCT (first transplant for tandem transplant patients) within 9 months 
after starting the first induction chemotherapy for high-risk neuroblastoma. In addition, patients were 
required to enroll in the study within 105 days post-ASCT (date of second transplant for tandem patients) 
such that study day 0 (first dose of sargramostim) occurred within 110 days post-transplantation
b Radiotherapy may have been waived for patients who either had a small adrenal mass that was com-
pletely resected initially or who never had an identifiable primary tumor
c Patients may not have had an identifiable primary tumor
Characteristic Sequence 1 (n = 14)
(UTC/NCI)
Sequence 2 (n = 14)
(NCI/UTC)
Mean age at randomization (range) 
(years)
4 (2–7) 4 (1–9)
Male gender, n (%) 8 (57) 8 (57)
Ethnicity, n (%)
 Hispanic 4 (29) 2 (14)
 Not Hispanic 10 (71) 12 (86)
Race, n (%)
 White 12 (86) 11 (79)
 Asian 0 1 (7)
 Black/African American 2 (14) 1 (7)
 Unknown 0 1 (7)
Pre-ASCT response, n (%)
 Complete response 5 (36) 3 (21)
 Very good partial response 5 (36) 4 (29)
 Partial response 4 (29) 7 (50)
Number of ASCT, n (%)
 Single 13 (93) 14 (100)
 Tandema 1 (7) 0
Prior chemotherapy, n (%) 14 (100) 14 (100)
Radiotherapy, n (%) 12 (86)b 13 (93)
Cancer-related surgery, n (%) 12 (86)c 11 (79)
1
10

































Fig. 1  Representative semilog (a) and linear (b) concentration–time profiles from a single patient for ch14.18-UTC and ch14.18-NCI
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analysis, which utilized a population pharmacokinetic 
approach. In addition, Desai et al. used different pharma-
cokinetic software (MLAB; Civilized Software, Silver 
Spring, MD). Despite these differences, mean pharmacoki-
netic parameters for the CHP1002 study were compara-
ble between the Desai analysis and the population model. 
When pharmacokinetic parameters are expressed in terms 
of nominal ch14.18-NCI dosing units, estimates for the 
Desai analysis and the population pharmacokinetic analy-
sis, respectively, are similar (CL, 2.1 vs. 1.9 L/d/m2; Vl, 2.2 
vs. 1.9 L; Kel, 0.026 vs. 0.027 1/h; Kcp, 0.021 vs. 0.023 
1/h; and Kpc, 0.010 vs. 0.015 1/h).
Overall, the TRAEs (including allergic-type events) 
observed in this study were consistent with those reported 
in other studies in which ch14.18 was administered with 
growth factors and cytokines [12, 15]. The most commonly 
reported adverse events in >60 % of patients, regardless of 
manufacturer, were pyrexia, hypoalbuminemia, hypoka-
lemia, hyponatremia, cough, increased ALT, anemia, 
hypocalcemia, pain, pruritus, increased AST, hypertriglyc-
eridemia, and abdominal pain.
The ANBL0032 study demonstrated that approximately 
17 % of patients treated with ch14.18 develop HACA, with 
<5 % having a neutralizing antibody response in a biologi-
cal assay (data on file, United Therapeutics Corporation). 
Table 3  Patients’ completion or discontinuation of study therapy
NCI National Cancer Institute, UTC United Therapeutics Corporation
a One patient excluded because of interfering human anti-chimeric 
antibodies, for the pharmacokinetic assay
b Patients completed cycles 1–5 and went on to complete scheduled 
course of isotretinoin in their country
c Patient discontinued during cycle 3 due to serum sickness
d Patient discontinued during cycle 2 due to neuropathy






Safety population, n 14 14
Pharmacokinetic population, n 13a 14
Completed all study therapy 9 (64) 12 (86)
Discontinued study therapy
 Cycle 1 1 (7) 0
 Cycle 2 0 1 (7)
 Cycle 3 2 (14) 0
 Cycle 4 0 1 (7)
 Cycle 5 2 (14)b 0
Reason for study discontinuation
 Disease progression 1 (7) 1 (7)
 Adverse event 1 (7)c 1 (7)d
 Consent withdrawn 1 (7) 0
 Moved out of country 2 (14)b 0
Table 4  Summary of individual post hoc pharmacokinetic parameter 
estimates for ch14.18
CL clearance from the central compartment, Kcp first-order distribu-
tion rate constant (central-to-peripheral), Kel first-order elimination 
rate constant, Kpc first-order distribution rate constant (peripheral-
to-central), NCI National Cancer Institute, Q distributional clearance, 
UTC United Therapeutics Corporation, V1 volume of the central 
compartment, V2 volume of the peripheral compartment, Vss steady-











CL (L/d) 0.683 (0.307) 0.75 (0.32) 0.709 (0.315)
CL (L/d/m2) 1.09 (0.457) 1.17 (0.455) 1.12 (0.457)
Q (L/d) 0.767 (0.163) 0.956 (0.213) 0.857 (0.198)
Q (L/d/m2) 1.20 (0.026) 1.46 (0.023) 1.32 (0.056)
V1 (L) 1.43 (0.403) 1.36 (0.42) 1.40 (0.404)
V1 (L/m2) 2.23 (0.29) 2.05 (0.28) 2.15 (0.28)
V2 (L) 3.94 (1.1) 3.76 (1.09) 3.85 (1.07)
V2 (L/m2) 6.10 (0.42) 5.65 (0.40) 5.87 (0.39)
Vss (L) 5.38 (1.47) 5.12 (1.49) 5.25 (1.45)
Vss (L/m
2) 8.32 (0.57) 7.70 (0.57) 8.03 (0.54)
Kel (1/d) 0.489 (0.211) 0.569 (0.232) 0.520 (0.221)
Kcp (1/d) 0.552 (0.073) 0.723 (0.103) 0.630 (0.090)
Kpc (1/d) 0.199 (0.018) 0.259 (0.021) 0.228 (0.018)
Table 5  Grade 3 or higher treatment-related adverse events (≥10 %)
ALT alanine aminotransferase, NCI National Cancer Institute, UTC 
United Therapeutics Corporation
a ALT increases were transient




≥1 Adverse event 22 (81.5) 23 (85.2)
Pyrexia 13 (48.1) 12 (44.4)
Anemia 6 (22.2) 9 (33.3)
Hypokalemia 7 (25.9) 7 (25.9)
Hyponatremia 5 (18.5) 5 (18.5)
Platelet count decreased 4 (14.8) 5 (18.5)
ALT increaseda 4 (14.8) 1 (3.7)
Lymphocyte count decreased 2 (7.4) 3 (11.1)
Pain-related adverse events
 Pain 5 (18.5) 2 (7.4)
 Pain in extremity 2 (7.4) 3 (11.1)
 Abdominal pain 2 (7.4) 3 (11.1)
Hypocalcemia 3 (11.1) 2 (7.4)
Hypotension 2 (7.4) 3 (11.1)
Neutrophil count decreased 2 (7.4) 3 (11.1)
Hypoxia 1 (3.7) 3 (11.1)
Urine output decreased 3 (11.1) 1 (3.7)
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In this study, 6/27 (22 %) of patients had confirmed HACA, 
and only one patient was excluded from the pharmacoki-
netic analysis due to a neutralizing antibody response.
In summary, the current analysis confirms that the 
ch14.18-UTC dose of 17.5 mg/m2 is comparable to the 
ch14.18-NCI dose of 25 mg/m2 in terms of systemic expo-
sure and with no notable safety and tolerability differences.
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